Compounds > fulvestrant
Page last updated: 2024-08-26

fulvestrant and Response Evaluation Criteria in Solid Tumors

fulvestrant has been researched along with Response Evaluation Criteria in Solid Tumors in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Goetz, MP; Haddad, N; Hurt, KC; Iwata, H; Kaufman, PA; Lu, Y; Neven, P; Rugo, HS; Sledge, GW; Toi, M; Tolaney, SM1
Arteaga, CL; Awada, A; Baselga, J; Campone, M; Chia, S; Clemons, M; Cortés, J; De Laurentiis, M; Dharan, B; Di Tomaso, E; Hachemi, S; Hurvitz, S; Im, SA; Ito, Y; Iwata, H; Jagiełło-Gruszfeld, A; Jiang, Z; Jonat, W; Massacesi, C; Masuda, N; Pistilli, B; Takahashi, M; Tseng, LM; Urban, P; Vuylsteke, P1
Bisagni, G; Colleoni, M; De Fato, R; Del Mastro, L; Frassoldati, A; Gianni, L; Mansutti, M; Valagussa, P; Viale, G; Zamagni, C; Zambetti, M1
Ellis, MJ; Fazal, M; Noguchi, S; Robertson, JFR; Shao, Z; Thirlwell, J1
Brufsky, A; Burnette, B; Cheema, P; Goldstein, LJ; Haley, B; Klein, P; Kornblum, N; Makower, DF; Manola, J; Miller, KD; Ramaswamy, B; Soori, GS; Sparano, JA; Stella, PJ; Telli, M; Truica, CI; Wassenaar, TR; Wolff, AC; Zhao, F1

Trials

5 trial(s) available for fulvestrant and Response Evaluation Criteria in Solid Tumors

ArticleYear
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
    Breast cancer research : BCR, 2021, 08-23, Volume: 23, Issue:1

    Topics: Adult; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Middle Aged; Premenopause; Progression-Free Survival; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Response Evaluation Criteria in Solid Tumors; Survival Rate

2021
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    The Lancet. Oncology, 2017, Volume: 18, Issue:7

    Topics: Aged; Alanine Transaminase; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Double-Blind Method; Drug Eruptions; Estradiol; Exanthema; Female; Fulvestrant; Humans; Hyperglycemia; Middle Aged; Morpholines; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Response Evaluation Criteria in Solid Tumors; Retreatment; Signal Transduction; Survival Rate

2017
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
    The Lancet. Oncology, 2018, Volume: 19, Issue:2

    Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Fulvestrant; Humans; Infusions, Intravenous; Injections, Intramuscular; Italy; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Piperazines; Prognosis; Proportional Hazards Models; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Response Evaluation Criteria in Solid Tumors; Survival Analysis; Trastuzumab; Treatment Outcome

2018
Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON).
    Breast cancer (Tokyo, Japan), 2018, Volume: 25, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast; Breast Neoplasms; China; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Japan; Middle Aged; Nitriles; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Response Evaluation Criteria in Solid Tumors; Taiwan; Triazoles

2018
Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 06-01, Volume: 36, Issue:16

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Double-Blind Method; Drug Synergism; Everolimus; Female; Fulvestrant; Humans; Middle Aged; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Response Evaluation Criteria in Solid Tumors; Survival Rate; Treatment Outcome

2018